CytoSorbents Reschedules Earnings Release to March 31, 2025 to Allow Additional Time to Complete Annual Audit

Core Viewpoint - CytoSorbents Corporation reaffirms its preliminary financial results for Q4 and full year 2024, expecting regulatory decisions on DrugSorb™-ATR marketing applications in 2025 [1][4] Financial Results - The company plans to report Q4 and full year 2024 financial results and file its Form 10-K after market close on March 31, 2025 [2] - Estimated Q4 2024 product revenue is projected to be between $9.0 million and $9.2 million, reflecting a growth of 22% to 25% compared to $7.35 million in Q4 2023 [8] - Full-year product revenue is expected to be between $35.4 million and $35.6 million, indicating approximately 14% growth from $31.1 million in 2023 [8] - The estimated cash balance as of December 31, 2024, is approximately $17.0 million, including $15.5 million in unrestricted cash, after accounting for recent fundraising activities [5] DrugSorb-ATR Marketing Applications - The marketing applications for DrugSorb-ATR are under substantive review by the U.S. FDA and Health Canada, with decisions anticipated in 2025 [4][11] - DrugSorb-ATR is designed to reduce perioperative bleeding in high-risk surgeries and has received two FDA Breakthrough Device Designations [11] Conference Call Details - A live conference call and presentation will be held on March 31, 2025, at 4:30 PM ET, with details provided for participants to join [7]